Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v53,p874)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, M. C.
Right arrow Articles by Cherrington, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, M. C.
Right arrow Articles by Cherrington, A. D.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:14-20, 2004
© 2004 by the American Diabetes Association, Inc.

Portal Serotonin Infusion and Glucose Disposal in Conscious Dogs

Mary Courtney Moore1, W. Blair Geho2, Margaret Lautz1, Ben Farmer1, Doss W. Neal1, and Alan D. Cherrington1,3

1 Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee
2 SDG, Cleveland, Ohio
3 Diabetes Research and Training Center, Vanderbilt University School of Medicine, Nashville, Tennessee

Whether serotonin (5-hydroxytryptamine [5-HT]) enhances net hepatic glucose uptake (NHGU) during glucose infusion was examined in conscious 42-h-fasted dogs, using arteriovenous difference and tracer ([3-3H]glucose) techniques. Experiments consisted of equilibration (-120 to -30 min), basal (-30 to 0 min), and experimental (0–390 min) periods. During the experimental period, somatostatin, fourfold basal intraportal insulin, basal intraportal glucagon, and peripheral glucose (to double the hepatic glucose load) were infused. In one group of dogs (SER; n = 8), saline was infused intraportally from 0 to 90 min (P1), and 5-HT was infused intraportally at 10, 20, and 40 µg · kg-1 · min-1 from 90 to 150 (P2), 150 to 210 (P3), and 210 to 270 (P4) min, respectively. In the other group (SAL; n = 8), saline was infused intraportally from 0 to 270 min. NHGU in SAL was 12.4 ± 2.3, 14.9 ± 2.7, 13.4 ± 2.1, and 15.1 ± 1.8 µmol · kg-1 · min-1 in P1 to P4, respectively, whereas NHGU in SER averaged 13.2 ± 3.0, 16.4 ± 2.4, 19.0 ± 2.4 (P < 0.05 vs. SAL), and 22.0 ± 2.9 µmol · kg-1 · min-1 (P < 0.05 vs. SAL). Nonhepatic glucose uptake (µmol · kg-1 · min-1) in SAL was 31.7 ± 4.9, 43.9 ± 5.1, 55.1 ± 5.6, and 66.2 ± 8.6 during P1 to P4, respectively, whereas in SER, the corresponding values were 26.1 ± 5.7, 31.6 ± 9.4, 35.1 ± 7.6 (P < 0.05 vs. SAL), and 34.7 ± 7.7 (P < 0.05 vs. SAL). Intraportal 5-HT enhances NHGU but blunts nonhepatic glucose uptake, raising the possibility that hepatic-targeted 5-HT or 5-HT receptor agonists might reduce postprandial hyperglycemia.


Address correspondence and reprint requests to Mary C. Moore, PhD, 702 Light Hall, Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615. E-mail: genie.moore{at}mcmail.vanderbilt.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, K. Kimura, H. Shibata, T. Honjoh, M. Saito, C. A. Everett, M. S. Smith, and A. D. Cherrington
Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E225 - E231.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, C. A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, and A. D. Cherrington
Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs
Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E556 - E563.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, C. A. DiCostanzo, D. Dardevet, M. Lautz, B. Farmer, D. W. Neal, and A. D. Cherrington
Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs
Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1057 - E1063.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.